anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A hybrid cell (I) comprising a mature dendritic cell (DC) fused to a non-dendritic cell which is freshly isolated or obtained from a primary cell culture and where DC and non-DC are allogeneic to each other, is new. Independent claims are also included for the following: (1) making (M1) (I) comprising subjecting a population of mature DCs and non-DCs allogeneic to the DCs to conditions that promote cell fusion; (2) a kit comprising a sample containing a population of mature DCs in one or more containers and instructions for its use in treating or preventing cancer or an infectious disease or in making (I); (3) treating or preventing (M2) cancer or an infectious disease in a mammal comprising administering a therapeutically active amount of (I) which shares at least one class I major histocompatibility complex (MHC) allele with the mammal; and (4) preventing a cancer in an individual having a predisposition for the cancer comprising M2 where the non-dendritic cell displays the antigenicity of an antigen associated with the cancer. - ACTIVITY : Cytostatic; Antibacterial; Virucide; Protozoacide; Antiparasitic. The effect of the hybrid cells as vaccines for treating cancer was studied in 17 patients with renal cell carcinoma. The hybrid cells were formed by electrofusion of 5 X 10 to the power of 7> autologous cells derived from renal cell carcinoma tissue with 5 X 10 to the power of 7> allogeneic dendritic cells. After electrofusion and irradiation with 200 Gy, the vaccine was immediately injected. Freshly-prepared booster vaccinations were administered after 6 weeks, followed by a re-evaluation of the patients 6 weeks later. After 13 months, 4 patients completely rejected all metastatic tumor lesions, one presented a mixed response, and 2 had a tumor mass reduction of greater than 50%. This demonstrated induction of human leukocyte antigen (HLA)-A2-restricted cytotoxic T cells reactive with the MucI tumor-associated antigen and recruitment of CD8+ lymphocytes into tumor challenge sites. The hybrid cell vaccination was well tolerated by all patients and there were no serious adverse effects. These results indicated that hybrid cell vaccination was a safe and effective therapy for renal cell carcinoma. - MECHANISM OF ACTION : Vaccine.
The invention provides a human bone morphogenetic protein 2 coding sequence, wherein the human bone morphogenetic protein 2 gene has a nucleotide sequence with a structure of (a) or (b); wherein the nucleotide sequence of (a) is shown as SEQ ID NO. 1; the nucleotide sequence of (b) has at least 90% homology with the nucleotide sequence shown in SEQ ID NO. 1, and has the same function as SEQ ID NO. 1 and can code human bone morphogenetic protein 2. According to the invention, an optimized human bone morphogenetic protein 2 coding sequence suitable for the expression system is designed according to the escherichia coli expression system, and a higher expression quantity of the target protein is obtained by optimizing codons. The invention also provides a purification method of the human bone morphogenetic protein 2 expressed by the escherichia coli expression system, and the human bone morphogenetic protein 2 with the purity of more than 95% can be obtained by the purification method.
In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
An adequate supply of O2 is essential for the maintenance of cellular activity. Systemic or local hypoxia can be experienced during decreased O2 availability or associated with diseases, or a combination of both. Exposure to hypoxia triggers adjustments in multiple physiological systems in the body to generate appropriate homeostatic responses. However, with significant reductions in the arterial partial pressure of O2, hypoxia can be life-threatening and cause maladaptive changes or cell damage and death. To mitigate the impact of limited O2 availability on cellular activity, O2 chemoreceptors rapidly detect and respond to reductions in the arterial partial pressure of O2, triggering orchestrated responses of increased ventilation and cardiac output, blood flow redistribution and metabolic adjustments. In mammals, the peripheral chemoreceptors of the carotid body are considered to be the main hypoxic sensors and the primary source of excitatory feedback driving respiratory, cardiovascular and autonomic responses. However, current evidence indicates that the CNS contains specialized brainstem and spinal cord regions that can also sense hypoxia and stimulate brain networks independently of the carotid body inputs. In this manuscript, we review the discoveries about the functioning of the O2 chemoreceptors and their contribution to the monitoring of O2 levels in the blood and brain parenchyma and mounting cardiorespiratory responses to maintain O2 homeostasis. We also discuss the implications of the chemoreflex-related mechanisms in paediatric and adult pathologies.
Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. Risk factors for CVD include, obesity, high serum concentrations of low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides, and total cholesterol, as well as low serum concentrations of high-density lipoprotein (HDL) cholesterol. Hypertension (high blood pressure) is an additional risk factor for CVD. Dietary strategies to reduce the risk for CVD include consuming adequate amounts of fruits, vegetables, and whole grains. However, there is limited published research regarding the effects of specific food items on CVD risk factors. One such example are mangos; there are murine studies, but there is a paucity of human clinical trial research on the effects of mango consumption on decreasing the risk factors for CVD. Therefore, the objective of this proposed study will examine whether mango consumption lowers these CVD risk factors in individuals with hypertension and/or dyslipidemia. The hypothesis is that mango consumption will decrease LDL-cholesterol, VLDL-cholesterol, triglycerides, total cholesterol, body weight, and blood pressure, and increase HDL-cholesterol. This proposed study will follow a randomized, controlled, cross-over design. Blood draws will be performed at baseline, after 8 weeks, and at the end of each dietary treatment, at the Student Health Services at California State Polytechnic University, Pomona. In addition, height, body weight, and blood pressure measurements will be taken. Subsequently, lipid panels will be generated for each participant, and those with dyslipidemia and/or hypertension will consume either 1 cup of mango or vanilla wafers (iso-caloric control) per day for 16 weeks. After a 4-week washout period, the subjects will consume the other dietary treatment for 16 weeks. Two-way repeated measures Analysis of Variance (ANOVA), followed by least significant difference (LSD) post-hoc analysis, will be used to determine if there are significant differences in CVD risk factors between the mango and wafer diets. Furthermore, the participants will complete two 24-hour recalls during the week before each laboratory visit. It is expected that the consumption of mangos will decrease LDL-cholesterol, VLDL-cholesterol, triglycerides, total cholesterol, body weight, and blood pressure, and increase HDL-cholesterol compared to the wafer diet. This proposed study will be the first to determine the cardiovascular health benefits of mango consumption in humans.
The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medullablastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer- therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the 'sternness' pathway. The markers can be mRNA, microRNA, DNA, or protein.
No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
Large numbers of post-deployed U.S. veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and/or Traumatic Brain Injury make effective interventions urgent, to reduce symptoms and increase veterans' coping. PTSD includes anxiety, flashbacks, and emotional numbing. Symptoms expand health care costs for stress-related illnesses making veterans' civilian life difficult.

The proposed study used a randomized experimental design with repeated measures and waitlist control group testing the efficacy of a 6-week human-horse interaction and systematic therapeutic horseback riding program in: decreasing PTSD symptoms, increasing coping self efficacy, emotion regulation, and social engagement. The Riding Group spent one hour weekly interacting with and riding the same horse at one of two PATH-accredited riding centers in Mid-Missouri supervised by an Occupational Therapist, Profession Association of Therapeutic Horsemanship (PATH) International-certified instructor, leader and side walkers as needed. Riding was directed by a systematic lesson plan. Data collection occured at baseline, 3 weeks, and 6 weeks. The Control Group was assessed at the same intervals and again 3 weeks and 6 weeks after joining the Riding Group.
Chronic kidney disease affects 1 in 10 people globally, with a prevalence twenty times that of cancer. A subset of individuals will progress to end-stage renal disease (ESRD) where renal replacement therapy is required to maintain health. Cutaneous disease, including xerosis and pruritus, are endemic amongst patients with ESRD. In the uraemia-associated immune deficiency of ESRD, impaired circulating immune responses contribute to increased infection risk and poorer vaccination response. Clinical manifestations of dysregulated adaptive immunity within the skin have been well-described and have been posited to play a role in cutaneous features of ESRD. However, our understanding of the mechanisms by which adaptive immunity within the skin is affected by uraemia is relatively limited. We provide an overview of how the cutaneous adaptive immune system is impacted both directly and indirectly by uraemia, highlighting that much work has been extrapolated from the circulating immune system and often has not been directly evaluated in the skin compartment. We identify knowledge gaps which may be addressed by future research. Ultimately, greater understanding of these pathways may facilitate novel therapeutic approaches to ameliorate widespread cutaneous symptomatology in ESRD.
Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
Subjects were given 6 subcutaneous injects of PR1:169-177 in "Montanide" adjuvant and 6 subcutaneous injections of WT1:126-134 in "Montanide" adjuvant at 2 weekly intervals. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
Tele-medicine. Automated tele-cardiography concerns the transmission of a patient's electrocardiograms (ECGs) from his room via the microphone of a telephone apparatus and the telecommunications network. The ECG is sent directly to the mobile phone or FAX or e-mail address of the specific cardiologist of the patient's choice or the tele-cardiography subscriber's choice, through an automated process. The ECGs are recorded and entered into the telecommunications network via cardiographs- transmitters of modulated acoustic signals. The means of automation is the utilization of equipment and software of an IVR system (Interactive Voice Responce). It provides the cardiologists with the possibility of remote monitotring and consulting their patients, based on their cardiogram that will have been recorded just a few minutes beforehand.
Teratogenic Effects: Pregnancy Category C:

There are no adequate and well-controlled studies in pregnant women. Epinephrine crosses the placenta. Epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (fetal anoxia, spontaneous abortion, or both). Epinephrine is teratogenic in rabbits, mice, and hamsters dosed during organogenesis.

Epinephrine has been shown to have teratogenic effects (including gastroschisis and embryonic lethality) when administered subcutaneous in rabbits at approximately 15 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days). 

In mice, teratogenic effects (including embryonic lethality) were observed at approximately 3 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). 

In hamsters, teratogenic effects were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day for 4 days).
Community-Based Outpatient Clinics (CBOCs) from VA Integrated Service Network (VISN) 7 will be targeted, spanning the states of Alabama, Georgia, and South Carolina. VISN 7 CBOCs, serving at least 50 women Veterans with primary care services, will be recruited.
PCT No. PCT/US90/05228 Sec. 371 Date Mar. 12, 1992 Sec. 102(e) Date Mar. 12, 1992 PCT Filed Sep. 14, 1990.The invention provides an apparatus and method for the preparation of a pharmaceutical composition comprising a complex of an antigen component and the corresponding antibody component in a pharmacologically acceptable carrier. The apparatus comprises a housing chamber for containing paramagnetic particles and a platform against which the housing chamber is releasably retained. The platform contains one or more magnets located adjacent to the housing chamber when the housing chamber is positioned on the platform. The platform is secured to a support which allows the platform, and thus the housing chamber, to be rotated between a vertical and a horizontal position. The method involves supplying a quantity of paramagnetic particles bearing the antigen component to the housing chamber, introducing into the housing chamber a physiological fluid which contains the antibody component, mixing the paramagnetic particles and the physiological fluid to form an antigen component and antibody component complex on the paramagnetic beads, removing the physiological fluid from the housing chamber, and eluting the antigen component and antibody component complex from the paramagnetic beads in a pharmaceutically acceptable eluting solution.
Critical limb ischemia (CLI) is the most advanced stage of peripheral artery disease (PAD); which is estimated to affect more than 200 million people worldwide.(1) CLI classified as Rutherford category (RC) 4-6, includes ischemic rest pain and tissue loss.(2) The first line revascularization strategy for patients with CLI is endovascular percutaneous transluminal angioplasty (PTA).(3) The treatment of femoropopliteal lesions displays a huge anatomic challenge as this segment serves various biomechanical functions, Which makes endovascular treatment is challenging.(4) Plain balloon (PB) angioplasty for femoropopliteal artery disease has a high rate of procedural success and an acceptable safety profile, in spite of initially encouraging technical success after femoropopliteal (PTA), postprocedural restenosis remains the major challenge(5) Excessive extracellular matrix material synthesized by activated smooth muscle cells (SMC) in the media of the arteries leads to Neointimal hyperplasia and restenosis.(6) Restenosis resulting in loss of primary patency, late lumen loss (LLL), occlusion and/or the need for target lesion revascularization (TLR).(7) Drug-coated balloons (DCBs) inhibit the neointimal hyperplasia, the biological mechanism of restenosis formation, by application of cytostatic agents in a local therapeutic concentration.(8) The antiproliferative paclitaxel (PTX) seems to be the most effective therapeutic agent for DCBs due to local retention in the arterial wall.(9)
A novel glycosylated form of albumin designated EGA and isolated from biological fluids is further characterized by its cell growth promoting activity. A process of isolation of human or bovine glycosylated albumin is described. The EGA fractions have been identified by serological histochemical and biological assays as well as lectin reactivity. The growth-promoting effect of EGA is directed to various transformed cell lines and primary cells of mammalian origin. Hepatoma cells have been found to produce EGA, in vitro. Novel compositions of EGA containing media are provided for cell, tissue or organ culture.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic which exhibits a skin reparation effect of the useful components in an organic substance for a long period without using an antiseptic and excels in stability and safety, and its raw material.  <P>SOLUTION: Humus can be obtained by subjecting humus soil to light reaction while maintaining a water content of 50-80%, for example, for 3 to 12 months. Furthermore, a humus extract solution is obtained by extraction of the humus with water, for example, for 3-12 months. When this humus extract solution is mixed with a moisturizing agent such as glycerin and fermented, for example, for 6-12 months, a moisturizing liquid derived from humus can be obtained. This moisturizing liquid exhibits a moisturizing effect, a skin whitening effect, an anti-oxidizing effect, and a physiologically active effect and does not require incorporation of an antibacterial agent, an antioxidant, an antiseptic and the like. This moisturizing liquid is best for a cosmetic, particularly for a skin care lotion.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Difenoconazole (DIF) is a fungicide used to control various fungi. It is absorbed on the surface of different plants and contributes significantly to increased crop production. However, DIF is reported to exhibit toxicity to fungi and to aquatic plants, fish, and mammals, including humans, causing adverse effects. However, research on the impact of DIF on the mammary epithelial cells of herbivorous bovines is limited. DIF-induced damage and accumulation in the mammary glands can have direct and indirect effects on humans. Therefore, we investigated the effects and mechanisms of DIF toxicity in MAC-T cells. The current study revealed that DIF reduces cell viability and proliferation while triggering apoptotic cell death through the upregulation of pro-apoptotic proteins, including cleaved caspase 3 and Bcl-2-associated X protein (BAX), and the downregulation of leukemia type 2 (BCL-2). DIF also induced endoplasmic reticulum (ER) stress by increasing the expression of genes or proteins of Bip/GRP78, protein disulfide isomerase (PDI), activating transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), and endoplasmic reticulum oxidoreductase 1 Alpha (ERO1-Lα). We demonstrated that DIF induces mitochondria-mediated apoptosis in MAC-T cells by activating ER stress pathways. This cellular damage resulted in a significant increase in the expression of inflammatory response genes and proteins, including cyclooxygenase 2 (COX2), transforming growth factor beta 3 (TGFB3), CCAAT enhancer binding protein delta (CEBPD), and iNOS, in DIF-treated groups. In addition, spheroid formation by MAC-T cells was suppressed by DIF treatment. Our findings suggest that DIF exposure in dairy cows may harm mammary gland function and health and may indirectly affect human consumption of milk.
Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
BACKGROUND: Popliteal artery injury (PAI) is a challenging trauma that requires prompt and accurate treatment since the probability of lower-limb amputation increases with the ischemic time. Intravascular shunting and cross-limb vascular shunting (CLS) are used as temporary vascular shunting (TVS) methods to shorten the ischemic time for limb vascular injury. CLS involves sending blood from an artery in a healthy body part to a peripheral vessel in an injured part to immediately resume blood flow to the injured limb. For closed injuries including PAI, CLS may be performed without exploring and identifying the arterial stumps and it enables early reperfusion to the ischemic limb. We report the case series of traumatic PAI treated using CLS and verify the usefulness of CLS.
METHODS: All patients with traumatic PAI treated with CLS at our institution between August 2013 and December 2021 were included. Demographic and clinical patient characteristics were extracted from the medical records. Comorbid injuries, severity of acute limb ischemia based on the Rutherford grading scale, time from injury to reperfusion by CLS, time from injury to completion of artery, and the use of fasciotomy were investigated. As outcomes, we investigated the presence or absence of lower extremity amputation during the course of treatment.
RESULTS: We used CLS as treatment for 5 cases with traumatic PAI. Based on the Rutherford grading scale for acute limb ischemia, there were one limb with grade 2B and 4 with grade 3. Amputation of the lower extremities was avoided except for 1 extremity in which arterial reconstruction was not achieved due to unexplained cardiac arrest during surgery.
CONCLUSIONS: CLS enables early reperfusion of the injured limb and is effective as a TVS method for traumatic PAI with severe ischemia or soft tissue damage.